Results 111 to 120 of about 8,298 (167)

Antimalarial cabamiquine inhibits blood-stage of different field isolates of Plasmodium species. [PDF]

BMC Infect Dis
Dembele L, Aniweh Y, Soulama A, Sogore F, Diakité O, Diallo F, Dao F, Amenga-Etego LN, Demarta-Gatsi C, Spangenberg T, Djimde AA.   +10 more
europepmc   +1 more source

First TES in Djibouti: A Critical Milestone Amid Rising Regional Threats. [PDF]

Open Forum Infect Dis
Behaksra SW, Guelleh SK, Sisay S, Weldehana YA, Weyesa DM, Endale T, Hamad AA, Hundera NL, Alemayehu DH, Tafa EB, Louie W, Aranda-Diaz A, Shiferaw M, Ayele MK, Kassa FA, Lakew DH, Shimelash A, Kebede BA, Abdo M, Bezabih MK, Moussa YO, Tessema TS, Greenhouse B, Abdi AA, Khaireh BA, Tadesse FG.   +25 more
europepmc   +1 more source

Genotype Complexity Modulates Antimalarial Susceptibility in vitro. [PDF]

Infect Drug Resist
Egwu CO, Ajibaye O, Bojang F, Mbye H, Ntui-Njock VN, Drammeh NF, Oriero EC, Amambua-Ngwa A.   +7 more
europepmc   +1 more source

<i>Plasmodium falciparum</i> field isolates drug susceptibility in Mali. [PDF]

JAC Antimicrob Resist
Maiga FO, Dembele L, Dama S, Diakite O, Diallo F, Sogore F, Maiga M, Dao F, Dara N, Alhousseini ML, Traore OB, Djimde AA.   +11 more
europepmc   +1 more source

Defining safety parameters for first-trimester malaria treatment trials: stakeholder views from Real-Time Delphi survey. [PDF]

Malar J
Bivegete S, Barsosio H, El Gaaloul M, Kayentao K, Worrall E, Duparc S, Kaszubska W, Valea I, Hill J, Ter Kuile F, Dellicour S.   +10 more
europepmc   +1 more source

A Controlled Human Malaria Infection model for relapsing Plasmodium vivax

Duncan AD, Geraedts TJ, Manlutac D, Baker EC, van Heerden JK, Roberts TW, Rigby CA, Salkeld J, Hou MM, Megson C, Kashojhala K, Boyle J, Nwankwo C, Williams BG, McHugh K, Teo ZW, Rodrigues AS, Gladstone CA, Comma E, Mujadidi YF, Robinson H, Plested E, McCall MB, Bousema T, Gmeiner M, Bok J, Graumans W, van Gemert G, Cowan RE, Boyd A, Ekregbesi P, Owino N, Cho J, Nugent FL, Nielsen CM, Mordmüller B, Donnellan FR, Silk SE, Draper SJ, Minassian AM.   +39 more
europepmc   +1 more source

Genomic Surveillance of malaria reveals localized sporadic emergence of artemisinin partial resistance and wide-spread sulfadoxine-pyrimethamine resistance in Ghana

Dorvi IN, Kudakpo AY, Mensah C, Ngoi JM, Bandoh K, Ayeke DY, Mpere ME, Kuma CMK, Ahmed O, Sakyi M, Bamfo-Ennin R, Donkor E, Malm F, Ampeh EM, Mettle DNA, Yemi B, Tei-Maya F, Amoako EK, Unlu E, Dzabeng F, Morang’a CM, Amuzu DSY, Awandare GA, Amambua-Ngwa A, Amenga-Etego LN.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Gender Differences in Pharmacokinetics of Lumefantrine and Its Metabolite Desbutyl-Lumefantrine in Rats

Biopharmaceutics and Drug Disposition, 2012
ABSTRACTLumefantrine has been reported to be mainly bio‐transformed by cytochrome P450 isozyme 3A4 to desbutyl‐lumefantrine (DLF) in human liver microsomes. Since CYP3A is expressed in a sex specific manner in rats, it could be expected that the pharmacokinetics of lumefantrine would be changed in male rats compared with those in female rats.
Sheelendra Pratap Singh, Girish Kumar Jain   +1 more
exaly   +3 more sources

Enantioselective in vitro ADME, absolute oral bioavailability, and pharmacokinetics of (−)-lumefantrine and (+)-lumefantrine in mice

Xenobiotica, 2020
Lumefantrine (LFN) is a chiral antimalarial drug. Enantioselective in vitro attributes and absolute oral pharmacokinetics for (-)-LFN and (+)-LFN have been characterized in mice. No stereoselectivity was seen with either of the enantiomers when compared with rac-LFN in the executed in vitro studies (solubility, metabolic stability, protein binding ...
Bhavesh Babulal Gabani, Abhishek Dixit, Vinay Kiran, Ram Murthi Bestha, Balaji Narayanan, Nuggehally R. Srinivas, Ramesh Mullangi   +6 more
openaire   +2 more sources